147 related articles for article (PubMed ID: 19858256)
1. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Li F; Nandy P; Chien S; Noel GJ; Tornoe CW
Antimicrob Agents Chemother; 2010 Jan; 54(1):375-9. PubMed ID: 19858256
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619
[TBL] [Abstract][Full Text] [Related]
3. Levofloxacin pharmacokinetics in children.
Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
[TBL] [Abstract][Full Text] [Related]
5. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.
Sprandel KA; Schriever CA; Pendland SL; Quinn JP; Gotfried MH; Hackett S; Graham MB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4597-605. PubMed ID: 15561831
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).
Nelson M; Lever MS; Dean RE; Pearce PC; Stevens DJ; Simpson AJ
Antimicrob Agents Chemother; 2010 Sep; 54(9):3922-6. PubMed ID: 20625157
[TBL] [Abstract][Full Text] [Related]
8. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
Cook AM; Martin C; Adams VR; Morehead RS
Antimicrob Agents Chemother; 2011 Jul; 55(7):3240-3. PubMed ID: 21576432
[TBL] [Abstract][Full Text] [Related]
10. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.
Rodvold KA; Danziger LH; Gotfried MH
Antimicrob Agents Chemother; 2003 Aug; 47(8):2450-7. PubMed ID: 12878504
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
Rebuck JA; Fish DN; Abraham E
Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin pharmacokinetics in adult cystic fibrosis.
Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
Boselli E; Breilh D; Rimmelé T; Djabarouti S; Saux MC; Chassard D; Allaouchiche B
Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
[TBL] [Abstract][Full Text] [Related]
14. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
Yee SB; Hatkin JM; Dyer DN; Orr SA; Pitt ML
Comp Med; 2010 Dec; 60(6):461-8. PubMed ID: 21262133
[TBL] [Abstract][Full Text] [Related]
15. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
Nicolau DP; Sutherland C; Winget D; Baughman RP
Pulm Pharmacol Ther; 2012 Feb; 25(1):94-8. PubMed ID: 22210007
[TBL] [Abstract][Full Text] [Related]
16. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Tasso L; de Andrade C; Dalla Costa T
Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
